| Overview |
| bs-17324R-A350 |
| Topoisomerase II beta Polyclonal Antibody, ALEXA FLUOR® 350 Conjugated |
| IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Rat |
| Mouse, Dog, Cow, Sheep, Pig, Horse, Rabbit, Chimpanzee |
| Specifications |
| ALEXA FLUOR® 350 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human Topoisomerase II beta |
| 1-100/1626 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 7155 |
| Q02880 |
| Cytoplasm, Nucleus |
| Antigen MLAA 44; beta isozyme; DNA topoisomerase 2 beta; DNA topoisomerase 2-beta; DNA topoisomerase II 180 kD; DNA topoisomerase II; DNA topoisomerase II beta; DNA topoisomerase II beta isozyme; Top 2; TOP 2B; TOP IIB; Top2 beta; TOP2B; TOP2B_HUMAN; Top2beta; TOPIIB; Topo II beta; Topoisomerase (DNA) II beta 180kDa; Topoisomerase (DNA) II beta; Topoisomerase IIb; U937 associated antigen. |
| Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks. Indirectly ivolved in vitamin D-coupled transcription regulation via its association with the WINAC complex, a chromatin-remodeling complex recruited by vitamin D receptor (VDR), which is required for the ligand-bound VDR-mediated transrepression of the CYP27B1 gene. |
| Application Dilution |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz